DE69827021T2 - An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese - Google Patents

An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese Download PDF

Info

Publication number
DE69827021T2
DE69827021T2 DE69827021T DE69827021T DE69827021T2 DE 69827021 T2 DE69827021 T2 DE 69827021T2 DE 69827021 T DE69827021 T DE 69827021T DE 69827021 T DE69827021 T DE 69827021T DE 69827021 T2 DE69827021 T2 DE 69827021T2
Authority
DE
Germany
Prior art keywords
vector
target tissue
vegf
tissue
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69827021T
Other languages
German (de)
English (en)
Other versions
DE69827021D1 (de
Inventor
K. Todd ROSENGART
G. Ronald CRYSTAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/801,352 external-priority patent/US5846225A/en
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Application granted granted Critical
Publication of DE69827021D1 publication Critical patent/DE69827021D1/de
Publication of DE69827021T2 publication Critical patent/DE69827021T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
DE69827021T 1997-01-29 1998-01-29 An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese Expired - Fee Related DE69827021T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3660197P 1997-01-29 1997-01-29
US36601P 1997-01-29
US801352 1997-02-19
US08/801,352 US5846225A (en) 1997-02-19 1997-02-19 Gene transfer therapy delivery device and method
US7115698P 1998-01-13 1998-01-13
US71156P 1998-01-13
PCT/US1998/001638 WO1998032859A1 (en) 1997-01-29 1998-01-29 Multiple site delivery of adenoviral vector for the induction of angiogenesis

Publications (2)

Publication Number Publication Date
DE69827021D1 DE69827021D1 (de) 2004-11-18
DE69827021T2 true DE69827021T2 (de) 2005-02-24

Family

ID=27365066

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69827021T Expired - Fee Related DE69827021T2 (de) 1997-01-29 1998-01-29 An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese

Country Status (16)

Country Link
US (2) US6518255B2 (https=)
EP (1) EP1012291B1 (https=)
JP (1) JP2001509168A (https=)
KR (1) KR20000070572A (https=)
AT (1) ATE279518T1 (https=)
AU (1) AU745409B2 (https=)
BR (1) BR9806819A (https=)
CA (1) CA2278621A1 (https=)
DE (1) DE69827021T2 (https=)
HU (1) HUP0001964A3 (https=)
IL (1) IL131021A0 (https=)
MX (1) MXPA99006993A (https=)
NO (1) NO993669L (https=)
NZ (1) NZ336838A (https=)
PL (1) PL334902A1 (https=)
WO (1) WO1998032859A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
AU745409B2 (en) * 1997-01-29 2002-03-21 Cornell Research Foundation Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
US6775574B1 (en) * 1997-11-07 2004-08-10 Medtronic, Inc. Method and system for myocardial infarction repair
US6251079B1 (en) 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
US6458092B1 (en) 1998-09-30 2002-10-01 C. R. Bard, Inc. Vascular inducing implants
CA2348835A1 (en) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
AU5646300A (en) * 1999-02-10 2000-08-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of stimulating angiogenesis
US6986784B1 (en) 1999-05-14 2006-01-17 C. R. Bard, Inc. Implant anchor systems
US6440945B1 (en) * 1999-05-27 2002-08-27 Instituto Dermopatico Dell'immacolata Method of inducing angiogenesis in nonis chemic skeletal muscle
AU5624500A (en) * 1999-06-18 2001-01-09 Collaborative Group, Ltd., The Hyaluronic acid microspheres for sustained gene transfer
EP1067190A1 (en) * 1999-07-09 2001-01-10 Introgene B.V. Gene therapy for enhancing and/or inducing angiogenesis
US6855160B1 (en) 1999-08-04 2005-02-15 C. R. Bard, Inc. Implant and agent delivery device
WO2001010315A1 (en) 1999-08-05 2001-02-15 Cornell Research Foundation, Inc. Gene therapy platformed needle and method of administering a therapeutic solution to a heart
FR2799465B1 (fr) * 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
CA2389524A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6329348B1 (en) * 1999-11-08 2001-12-11 Cornell Research Foundation, Inc. Method of inducing angiogenesis
US7232421B1 (en) 2000-05-12 2007-06-19 C. R. Bard, Inc. Agent delivery systems
US6508802B1 (en) 2000-05-23 2003-01-21 Cornell Research Foundation, Inc. Remote sensing gene therapy delivery device and method of administering a therapeutic solution to a heart
US7204847B1 (en) 2000-07-28 2007-04-17 C. R. Bard, Inc. Implant anchor systems
US6939540B1 (en) 2000-07-31 2005-09-06 Cornell Research Foundation, Inc. Method of enhancing bone density
MXPA02003434A (es) * 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
WO2002036131A1 (en) * 2000-11-01 2002-05-10 Ludwig Institute For Cancer Research In vivo stimulation of angiogenic activity
EP1361896A2 (en) * 2001-01-23 2003-11-19 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
AR027161A1 (es) 2001-05-15 2003-03-19 Bio Sidus S A Metodo para inducir la proliferacion neovascular y regeneracion tisular
CA2406687A1 (en) * 2001-11-09 2003-05-09 Transgene S.A. Chimeric promoters for controlling expression in muscle cells
EP1560490A2 (en) * 2002-11-15 2005-08-10 Genvec, Inc. Coronary artery disease treatment
KR100912994B1 (ko) 2004-04-05 2009-08-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 Ｎｋｇ２ｄ의 조절
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
RU2321631C2 (ru) * 2005-06-24 2008-04-10 Государственное учреждение Российский научный центр хирургии РАМН Неинфекционный для человека аденовирус как вектор для заместительной генной терапии нарушений ангиогенеза, обеспечивающий эффективный синтез ангиогенина человека в трансфецированных клетках млекопитающих, способ индукции ангиогенеза, способ лечения ишемической болезни, композиция для индукции ангиогенеза и лечения ишемической болезни
US7751883B2 (en) 2006-04-25 2010-07-06 Eugenio Picano System and method for promoting coronary angiogenesis
US9598673B2 (en) * 2006-05-19 2017-03-21 Creative Medical Health Treatment of disc degenerative disease
US11224635B2 (en) 2007-03-27 2022-01-18 Venturis Thereuptics, Inc. Therapeutic angiogenesis for treatment of the spine and other tissues
US8983570B2 (en) 2007-03-27 2015-03-17 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treatment of the spine
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US8409147B2 (en) * 2009-08-22 2013-04-02 Joseph Wayne Kraft Rapid local anesthesia linear injection device
US8088108B2 (en) * 2009-08-22 2012-01-03 Joseph Wayne Kraft Rapid local anesthesia injection cone
CA2772610C (en) * 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
WO2014036222A1 (en) * 2012-08-30 2014-03-06 Emory University Systems, methods and computer readable storage media storing instructions for integrating fluoroscopy venogram and myocardial images
DK2945642T3 (da) * 2013-01-17 2024-05-27 Medizinische Hochschule Hannover Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
EP3259346B1 (en) 2015-02-20 2024-08-07 Baylor College of Medicine P63 inactivation for the treatment of heart failure
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
ES2932498T3 (es) 2016-12-05 2023-01-20 Nuritas Ltd Composiciones que comprenden el péptido WKDEAGKPLVK
CA3153845A1 (en) * 2019-10-09 2021-04-15 Rickey REINHARDT Epicardial delivery of gene therapy
WO2024233783A1 (en) 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510413A (en) 1893-12-12 Drainage-tube
US2551902A (en) 1948-09-10 1951-05-08 Arthur Schaffer Dehorning fluid ejector
US2670673A (en) 1950-07-17 1954-03-02 Joyce A Gordon Fluid injecting device
US3467096A (en) 1966-04-12 1969-09-16 Ferrell S Horn Multiple hypodermic syringe arrangement
FR1584474A (https=) 1968-02-20 1969-12-26
US3572336A (en) 1968-04-30 1971-03-23 Daniel R Hershberg Syringe
US4150669A (en) 1977-03-16 1979-04-24 Alvaro Latorre Apparatus for effecting and enhancing an erection
US4167179A (en) 1977-10-17 1979-09-11 Mark Kirsch Planar radioactive seed implanter
US5335670A (en) 1986-04-18 1994-08-09 Henry Fishman Allergy testing method and apparatus
JPS6438100A (en) 1987-07-31 1989-02-08 Toray Industries Vascular endothelial cell growth factor
JPH02117698A (ja) 1988-10-27 1990-05-02 Toray Ind Inc 血管内皮細胞成長因子
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
JPH02279698A (ja) 1989-04-20 1990-11-15 M K Medical:Kk 血管内皮細胞成長因子及びその製造方法
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
CA2017379C (en) 1989-05-24 2002-06-25 Kenneth A. Thomas, Jr. Purification and characterization of a glioma-derived growth factor
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
JPH03178996A (ja) 1989-12-06 1991-08-02 Makoto Goto 成長因子
US6228844B1 (en) * 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
EP0476983B1 (en) 1990-09-21 2000-03-15 Merck & Co. Inc. Vascular endothelial cell growth factor II
DE69229454T2 (de) 1991-03-28 2000-01-05 Merck & Co., Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US5244460A (en) 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
EP0550296A3 (en) 1991-11-28 1993-12-29 Terumo Corp Vascular endothelial cells growth factor
US5290258A (en) 1992-07-27 1994-03-01 Genesis Industries, Inc. Syringe for administering sequentially multiple doses of a medicament
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
ES2249762T3 (es) 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5417683A (en) 1994-07-13 1995-05-23 Shiao; I-Shen Mini-graft hair implanting device for implanting multiple clumps of hair follicles at one time
WO1996012406A1 (en) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
JP3178996B2 (ja) 1995-08-24 2001-06-25 沖電気工業株式会社 カード処理装置及びカード送り速度の制御方法
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5846225A (en) 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
AU745409B2 (en) * 1997-01-29 2002-03-21 Cornell Research Foundation Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
JP3371331B2 (ja) * 1998-12-14 2003-01-27 セイコーエプソン株式会社 インクジェット式記録ヘッドおよびその製造方法

Also Published As

Publication number Publication date
US6518255B2 (en) 2003-02-11
US20010041679A1 (en) 2001-11-15
US20030103943A1 (en) 2003-06-05
BR9806819A (pt) 2000-05-09
IL131021A0 (en) 2001-01-28
MXPA99006993A (es) 2005-06-01
AU745409B2 (en) 2002-03-21
JP2001509168A (ja) 2001-07-10
KR20000070572A (ko) 2000-11-25
NO993669L (no) 1999-09-27
HUP0001964A2 (hu) 2000-10-28
NO993669D0 (no) 1999-07-28
PL334902A1 (en) 2000-03-27
AU6253098A (en) 1998-08-18
EP1012291B1 (en) 2004-10-13
NZ336838A (en) 2002-04-26
WO1998032859A1 (en) 1998-07-30
ATE279518T1 (de) 2004-10-15
HUP0001964A3 (en) 2002-01-28
CA2278621A1 (en) 1998-07-30
DE69827021D1 (de) 2004-11-18
EP1012291A1 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
DE69827021T2 (de) An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese
DE69738640T2 (de) Räumliche und temporäre kontrolle der genexpression mittels eines hitzeschockproteinpromotors in kombination mit lokaler hitze
US4296100A (en) Method of treating the heart for myocardial infarction
US4378347A (en) Composition for treating the heart for myocardial infarction
DE69434069T2 (de) Gentherapie für solide tumoren, papillome und warzen
EP1687032B1 (en) Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
DE69526853T2 (de) Hemmung der fortpflanzung von arterienglattmuskelzellen
JPH10501423A (ja) 遺伝子転移媒介の血管形成療法
ES2895421T3 (es) ARN modificado que codifica polipéptidos de VEGF-A, formulaciones y usos relacionados con los mismos
WO2003039458A2 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
Lee et al. Cardiac gene transfer by intracoronary infusion of adenovirus vector—mediated reporter gene in the transplanted mouse heart
US6329348B1 (en) Method of inducing angiogenesis
EA019099B1 (ru) Способ направленной доставки трансгена в миокард пациента с ишемией миокарда
Tanaka et al. Amelioration of microvascular myocardial ischemia by gene transfer of vascular endothelial growth factor in rabbits
EA009390B1 (ru) Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом
JP2004534509A (ja) 内皮細胞特異性を示すプロモーター及びその使用法
US20050191278A1 (en) Coronary artery disease treatment
JP2022551911A (ja) 遺伝子治療の心外膜送達
Wirth et al. Sustained capillary enlargement induced by angiogenic gene therapy does not support post-ischemic muscle recovery of hyperlipidemic mice
HK1008979B (en) Gene transfer-mediated angiogenesis therapy

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee